Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KAT2B | Q92831 | 1/20 | 0.32 |
| ▸ | TYK2 | P29597 | 1/20 | 0.32 |
| ▸ | APP | P05067 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | GCK | P35557 | 1/20 | 0.30 |
| ▸ | CLK1 | P49759 | 1/20 | 0.30 |
| ▸ | CLK2 | P49760 | 1/20 | 0.30 |
| ▸ | P2RX3 | P56373 | 1/20 | 0.30 |
| ▸ | P2RX2 | Q9UBL9 | 1/20 | 0.30 |
| ▸ | ATM | Q13315 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL563652 | 0.94 | GCK (0.33) | KAT2BTYK2APPMAPTGCK | |
| SCHEMBL563780 | 0.93 | GCK (0.34) | APPMAPTGCK | |
| SCHEMBL10240492 | 0.91 | APP (0.31) | APPMAPTGCKP2RX3P2RX2 | |
| SCHEMBL564803 | 0.90 | — | — | |
| SCHEMBL564469 | 0.88 | GCK (0.32) | KAT2BTYK2GCK | |
| SCHEMBL564443 | 0.87 | GCK (0.36) | APPMAPTGCKP2RX3P2RX2 | |
| SCHEMBL564516 | 0.86 | GCK (0.34) | GCKATM | |
| SCHEMBL563612 | 0.85 | GCK (0.35) | KAT2BTYK2GCK | |
| SCHEMBL10240411 | 0.85 | GCK (0.33) | APPMAPTGCKP2RX3P2RX2 | |
| SCHEMBL1677382 | 0.85 | GCK (0.34) | MAPTGCK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8557805-B2 | Fused ring compound and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2013-10-15 | — | — | US | disclosed |
| US-8557805-B2 | Fused ring compound and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2013-10-15 | — | — | US | disclosed |
| US-20120035163-A1 | NOVEL FUSED RING COMPOUND AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED | 2012-02-09 | — | — | US | disclosed |
| US-20120035163-A1 | NOVEL FUSED RING COMPOUND AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED | 2012-02-09 | — | — | US | disclosed |
| EP-2371826-A1 | NOVEL FUSED RING COMPOUND AND USE THEREOF | Takeda Pharmaceutical Company Limited (JP) | 2011-10-05 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120035163-A1 | NOVEL FUSED RING COMPOUND AND USE THEREOF | GPR119, GCKR, SLC5A1 | KAT2B 973/4885TYK2 3812/4885APP 2797/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.